Tarsus buys iRenix Medical for $75M to add late-stage eye drug

What's the deal? Tarsus Pharmaceuticals (Nasdaq: TARS) has acquired iRenix MedicalDealroom has a profile for this one. Try Dealroom →, a clinical-stage ophthalmic biopharmaceutical company, for roughly $75 million upfront. Under the July 6, 2026 merger agreement, iRenix became a wholly-owned subsidiary of Tarsus.

The terms: The upfront consideration splits into $37.5 million in cash and 607,093 shares of Tarsus common stock valued at about $37.5 million. iRenix equityholders can earn up to $490 million in milestone payments tied to regulatory approvals and commercial sales, plus low-to-mid single-digit revenue sharing on certain products.

What's the endgame? The deal centres on IRX-101, a late-stage investigational ocular antiseptic based on a stable aqueous chlorine dioxide solution. It is designed to reduce post-procedural pain and corneal toxicity in patients receiving intravitreal therapy.

Why now? IRX-101 is backed by positive Phase 2b/3 data and is about to enter an FDA-aligned Phase 3 programme, giving Tarsus a near-term path toward registration and commercialisation.

Tarsus already sells XDEMVY for Demodex blepharitis and is developing TP-04 for ocular rosacea and TP-05 for Lyme disease prevention, both in Phase 2. IRX-101 adds a late-stage asset targeting a multi-million patient population facing vision loss.

What could go wrong? The milestone-heavy structure caps upfront risk, but up to $490 million in extra payments hinge on IRX-101 clearing regulatory and commercial hurdles. There is also a risk that the upcoming Phase 3 trial fails to replicate earlier results. Part of the consideration sits in escrow to cover indemnification and post-closing adjustments.

The signal: By weighting most of the deal toward milestones and revenue sharing, Tarsus is buying late-stage optionality without a heavy cash outlay — a structure that ties iRenix sellers' payouts to whether IRX-101 reaches the market.

Read more: Minichart